3 Reasons Alnylam Is a Top Biotech Stock to Buy Right Now
We don't know how many different rare diseases there are right now that need better treatment options, but Alnylam (NASDAQ: ALNY) is chipping away at the stone with a jackhammer. The company successfully launched its first rare disease drug last spring and already expects a fourth new drug approval by the end of 2020.
Alnylam's shown us its RNA interference platform is capable of churning out dozens of successful new drugs, but the science behind its drugs isn't the only ingredient in the company's sauce. Alnylam's also pioneering a win-win-win solution for rare disease drugmakers, the patients relying on them, and risk weary end payers.
Image source: Getty Images.
Source Fool.com
